Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.

1:35 Individualized Care for PC

9:24 Frailty & Comorbidities in PC

12:27 Molecular Testing in PC

18:10 Sequencing in PC

22:00 Doublets/Triplets in mHSPC

30:00 Subgroups in mHSPC

39:00 ARASENS Subgroup Analysis

43:55 Future of mHSPC Care

Wayne Kuang, MD; and Matt T. Rosenberg, MD, discuss how overactive bladder presents with distinct pathophysiological mechanisms between genders, requires different diagnostic approaches when distinguishing from benign prostatic hyperplasia in men, impacts quality of life in older adults, benefits from early primary care intervention, and necessitates improved patient advocacy and educational initiatives for optimal management outcomes.

Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.

1:54 mHSPC and Imaging

4:57 Current SOC in mHSPC

10:15 Choosing Therapy in mHSPC

18:51 ARANOTE Trial in mHSPC

21:15 Experience With ARI

27:08 Emerging mHSPC Treatments

32:51 ARANOTE Subgroup Analysis

35:31 Future Outlook for mHSPC

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

In this episode of Speaking of Urology®, former Major League Baseball (MLB) player, Dave Winfield, shares lessons he’s learned throughout his professional baseball career and his work in philanthropy. Winfield delivered a keynote presentation at this year’s LUGPA Annual Meeting titled, “Leadership Lessons Learned from Baseball, Business and Philanthropy.”

In this episode of Speaking of Urology®, Juan J. Andino, MD, MBA, speaks with Robert E. Brannigan, MD on the recent amendment to the American Urological Association (AUA) guideline on male infertility. This discussion originally took place during a live X (formerly Twitter) Spaces event held by Urology Times®.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen. Winter is a urologist and sexual medicine expert in Los Angeles, California.